Pandemic influenza: An inconvenient mutation

Science

Volumn 323, Issue 5921, 2009, Pages 1560-1561

  Layne, Scott P ^a   Monto, Arnold S ^b   Taubenberger, Jeffery K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC VARIABILITY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LETTER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; VIRUS STRAIN;

ANTIVIRAL AGENTS; DISASTER PLANNING; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; OSELTAMIVIR; REASSORTANT VIRUSES;

EID: 62849121367     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.323.5921.1560     Document Type: Letter

References (6)

1. N. J. Dharan et al., JAMA, 10.1001/jama.2009.294, published online 2 March 2009.
2. M. E. Halloran et al., Proc. Natl. Acad. Sci. U.S.A. 105, 4639 (2008).
3. A. S. Monto, Clin. Infect. Dis. 48, 397 (2009).
4. The United States has stockpiled 81 million doses of oseltamivir - one dose each for 25% of the population.
5. D. M. Morens, J. K. Taubenberger, A. S. Fauci, J. Infect. Dis. 198, 962 (2008).
6. This research was supported in part by the Intramural Research Program of the NIAID and the NIH.